 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/614523
Partnering with Bigpharma: The Definitive Guide to Partnering Interests, Contacts & Agreements
|
Description: |
This report provides the most comprehensive and in-depth insight into the business development, licensing and partnering interests and activity of the worlds leading fifty biopharma companies, providing all the information you require to better understand bigpharma partnering.
One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 200 charts allow quick understanding of each bigpharma companies dealmaking trends over the last four years.
This report contains over 1,200 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Key benefits:
Partnering with Bigpharma provides the user with the following key benefits:
- Detailed company profiles for each of the top 50 bigpharma companies
- Over 200 charts showing a company’s dealmaking activity since 2005, allowing quick identification potential partners
- In-depth marketed and pipeline product activity of each company
- Partnering interests and therapy focus revealed
- Partnering activity since 2000 – number of deals per year
- Partnering activity for 2005-2008
- Activity by deal type
- Activity by phase of development
- Activity by therapeutic area
- List of recent partner companies
- Comprehensive access to over 1,200 actual contracts entered into by the leading fifty biopharma companies*
- Insight into the terms included in a partnering agreement, together with real world clause examples
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
*Subject to being published via regulatory requirements of the Securities Exchange Commission.
Report scope:
Partnering with Bigpharma is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.
Partnering with Bigpharma includes:
Detailed company profiles for each of the top 50 bigpharma companies, including:
- Full contact details
- Business developer contact details including name, title, email and telephone (where available)
- Marketed indications
- Pipeline indications
- Partnering interests and indications
- Partnering activity since 2000
- Current partner companies since 2005
Partnering activity since 2005 by:
- Deal type
- Stage of development
- Therapy area
- Over 200 charts showing the dealmaking activity of each company since 2005
- The tools to enable effective and efficient preparation for partnering negotiation with bigpharma
- Listing of over 1,200 contract documents between bigpharma and partner companies
- The leading M&A and partnering deals by value 2005-8
- Most active M&A and partnering dealmakers 2005-8
The Partnering with Bigpharma report also provides comprehensive access to available contract documents for each of the fifty bigpharma companies. Analyzing actual company agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal? How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subscontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
For each company in Partnering with Bigpharma report, the available contracts are listed by deal type, including:
- Co-development
- Co-marketing
- Co-promotion
- Collaborative R&D
- Development
- Distribution
- Joint venture
- Licensing
- M&A
- Manufacturing
- Marketing
- Promotion
- Research
- Supply |
|
Contents: |
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Bigpharma – The Top 50
Chapter 3 – Most active bigpharma dealmakers
3.1 Bigpharma M&A activity
3.2 Bigpharma partnering
Chapter 4 – Top bigpharma deals – 2000-7
4.1 Bigpharma M&A
4.2 Bigpharma partnering
Chapter 5 – Submitting Opportunities to Bigpharma
5.1 How to submit an opportunity
5.2 Opportunity submission template
5.3 Sending emails
5.4 Face to face at partnering events
5.5 Online submission forms
Chapter 6 – Forthcoming bigpharma partnering events
6.1 Forthcoming events
Chapter 7 – Bigpharma company – therapy locator
7.1 How to use the therapy matrix tables
7.2 Therapeutic area definitions
7.3 Bigpharma – Therapeutic target matrix – marketed and pipeline compounds
7.5 Bigpharma – Therapeutic target matrix – expressed partnering interests
7.6 Bigpharma – Therapeutic target matrix – recent deals – 2005-2007
Chapter 8 – Bigpharma Company Profiles
8.1 How to use company profiles
8.2 Field definitions
8.3 Company profiles
Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Barr Pharmaceuticals
Baxter International
Bayer
Biogen Idec
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Chugai
CSL
Daiichi Sankyo
Eisai
Eli Lilly
Forest Laboratories
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
King
Lundbeck
Menarini
Merck & Co
Merck Serono KGaA
Mitsubishi-Tanabe
Mundipharma
Novartis AG
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Procter & Gamble
Ratiopharm
Roche
Sanofi-Aventis
Schering Plough
Servier
Shire
Solvay
Stada
Takeda
Teva
UCB
Watson
Wyeth
About CurrentPartnering
Recent report titles from CurrentPartnering
Order Form – Reports
Order Form – Report Update Subscription
Order form – Company Dealmaking Profiles
Order Form – CD-Rom
List of Figures
Figure 1: Bigpharma – top 50 by pharma revenues 2007
Figure 2: Leading Bigpharma M&A companies, 2005-7
Figure 3: Leading Bigpharma partnering companies, 2005-7
Figure 4: Leading M&A deals involving bigpharma by value, 2005-7
Figure 5: Leading partnering deals by value, 2005-7
Figure 6: Typical partnering opportunity submission template
Figure 7: Partnering events 2008-9
Figure 8: Therapeutic area definitions
Figure 9: Therapeutic target matrix – marketed and pipeline compounds
Figure 10: Therapeutic target matrix – expressed partnering interests
Figure 11: Therapeutic target matrix – recent deals 2005-7
Figure 12: Company profile template and definitions used in report
Figure 13: Abbott – Dealmaking frequency 2000-2007
Figure 14: Abbott - recent deals (2005-2008) by deal type
Figure 15: Abbott - recent deals (2005 – 2008) by stage of development
Figure 16: Abbott – recent deals (2005 – 2008) by therapy area
Figure 17: Recent Abbott partnering deals (2003-2008) where contract document available
Figure 18: Actavis – Dealmaking frequency 2000-2007
Figure 19: Actavis - recent deals (2005-2008) by deal type
Figure 20: Actavis - recent deals (2005 – 2008) by stage of development
Figure 21: Actavis – recent deals (2005 – 2008) by therapy area
Figure 22: Recent Actavis partnering deals (2003-2008) where contract document available
Figure 23: Alcon Labs dealmaking frequency 2000-2007
Figure 24: Alcon Labs - recent deals (2005 - 2008) by deal type
Figure 25: Alcon Labs - recent deals (2005 – 2008) by stage of development
Figure 26: Alcon Labs – recent deals (2005 – 2008) by therapy area
Figure 27: Recent Alcon Labs partnering deals (2003-2008) where contract document available
Figure 28: Allergan – Dealmaking frequency 2000-2007
Figure 29: Allergan - recent deals (2005-2008) by deal type
Figure 30: Allergan - recent deals (2005 – 2008) by stage of development
Figure 31: Allergan – recent deals (2005 – 2008) by therapy area
Figure 32: Recent Allergan partnering deals (2003-2008) where contract document available
Figure 33: Amgen – Dealmaking frequency 2000-2007
Figure 34: Amgen - recent deals (2005-2008) by deal type
Figure 35: Amgen - recent deals (2005 – 2008) by stage of development
Figure 36: Amgen – recent deals (2005 – 2008) by therapy area
Figure 37: Recent Amgen partnering deals (2003-2008) where contract document available
Figure 38: Astellas – Dealmaking frequency 2000-2007
Figure 39: Astellas - recent deals (2005-2008) by deal type
Figure 40: Astellas - recent deals (2005 – 2008) by stage of development
Figure 41: Astellas – recent deals (2005 – 2008) by therapy area
Figure 42: Recent Astellas partnering deals (2003-2008) where contract document available
Figure 43: AstraZeneca – Dealmaking frequency 2000-2007
Figure 44: AstraZeneca - recent deals (2005-2008) by deal type
Figure 45: AstraZeneca - recent deals (2005 – 2008) by stage of development
Figure 46: AstraZeneca – recent deals (2005 – 2008) by therapy area
Figure 47: Recent AstraZeneca partnering deals (2003-2008) where contract document available
Figure 208: Barr – Dealmaking frequency 2000-2007
Figure 219: Barr - recent deals (2005-2008) by deal type
Figure 220: Barr - recent deals (2005 – 2008) by stage of development
Figure 221: Barr – recent deals (2005 – 2008) by therapy area
Figure 222: Recent Barr partnering deals (2003-2008) where contract document available
Figure 48: Baxter – Dealmaking frequency 2000-2007
Figure 49: Baxter - recent deals (2005-2008) by deal type
Figure 50: Baxter - recent deals (2005 – 2008) by stage of development
Figure 51: Baxter – recent deals (2005 – 2008) by therapy area
Figure 52: Recent Baxter partnering deals (2003-2008) where contract document available
Figure 53: Bayer – Dealmaking frequency 2000-2007
Figure 54: Bayer - recent deals (2005-2008) by deal type
Figure 55: Bayer - recent deals (2005 – 2008) by stage of development
Figure 56: Bayer – recent deals (2005 – 2008) by therapy area
Figure 57: Recent Bayer partnering deals (2003-2008) where contract document available
Figure 58: Biogen Idec – Dealmaking frequency 2000-2007
Figure 59: Biogen Idec - recent deals (2005 – 2008) by deal type
Figure 60: Biogen Idec - recent deals (2005 – 2008) by stage of development
Figure 61: Biogen Idec – recent deals (2005 – 2008) by therapy area
Figure 62: Recent Biogen Idec partnering deals (2003-2008) where contract document available
Figure 63: Boehringer Ingelheim – Dealmaking frequency 2000-2007
Figure 64: Boehringer Ingelheim - recent deals (2005 – 2008) by deal type
Figure 65: Boehringer Ingelheim - recent deals (2005 – 2008) by stage of development
Figure 66: Boehringer Ingelheim – recent deals (2005 – 2008) by therapy area
Figure 67: Recent Boehringer Ingelheim partnering deals (2003-2008) where contract document available
Figure 68: Bristol-Myers Squibb – Dealmaking frequency 2000-2007
Figure 69: Bristol-Myers Squibb - recent deals (2005 – 2008) by deal type
Figure 70: Bristol-Myers Squibb - recent deals (2005 – 2008) by stage of development
Figure 71: Bristol-Myers Squibb – recent deals (2005 – 2008) by therapy area
Figure 72: Recent Bristol-Myers Squibb partnering deals (2003-2008) where contract document available
Figure 73: Chugai – Dealmaking frequency 2000-2007
Figure 74: Chugai - recent deals (2005-2008) by deal type
Figure 75: Chugai - recent deals (2005 – 2008) by stage of development
Figure 76: Chugai – recent deals (2005 – 2008) by therapy area
Figure 77: Recent Chugai partnering deals (2003-2008) where contract document available
Figure 78: CSL – Dealmaking frequency 2000-2007
Figure 79: CSL - recent deals (2005-2008) by deal type
Figure 80: CSL - recent deals (2005 – 2008) by stage of development
Figure 81: CSL – recent deals (2005 – 2008) by therapy area
Figure 82: Recent CSL partnering deals (2003-2008) where contract document available
Figure 208: DaiichiSankyo – Dealmaking frequency 2000-2007
Figure 219: DaiichiSankyo - recent deals (2005-2008) by deal type
Figure 220: DaiichiSankyo - recent deals (2005 – 2008) by stage of development
Figure 221: DaiichiSankyo – recent deals (2005 – 2008) by therapy area
Figure 222: Recent DaiichSankyo partnering deals (2003-2008) where contract document available
Figure 83: Eisai – Dealmaking frequency 2000-2007
Figure 84: Eisai - recent deals (2005-2008) by deal type
Figure 85: Eisai - recent deals (2005 – 2008) by stage of development
Figure 86: Eisai – recent deals (2005 – 2008) by therapy area
Figure 87: Recent Eisai partnering deals (2003-2008) where contract document available
Figure 88: Eli Lilly – Dealmaking frequency 2000-2007
Figure 89: Eli Lilly - recent deals (2005-2008) by deal type
Figure 90: Eli Lilly - recent deals (2005 – 2008) by stage of development
Figure 91: Eli Lilly – recent deals (2005 – 2008) by therapy area
Figure 92: Recent Eli Lilly partnering deals (2003-2008) where contract document available
Figure 93: Forest – Dealmaking frequency 2000-2007
Figure 94: Forest - recent deals (2005-2008) by deal type
Figure 95: Forest - recent deals (2005 – 2008) by stage of development
Figure 96: Forest – recent deals (2005 – 2008) by therapy area
Figure 97: Recent Forest partnering deals (2003-2008) where contract document available
Figure 98: Genentech – Dealmaking frequency 2000-2007
Figure 99: Genentech - recent deals (2005-2008) by deal type
Figure 100: Genentech - recent deals (2005 – 2008) by stage of development
Figure 101: Genentech – recent deals (2005 – 2008) by therapy area
Figure 102: Recent Genentech partnering deals (2003-2008) where contract document available
Figure 103: Genzyme – Dealmaking frequency 2000-2007
Figure 104: Genzyme - recent deals (2005-2008) by deal type
Figure 105: Genzyme - recent deals (2005 – 2008) by stage of development
Figure 106: Genzyme – recent deals (2005 – 2008) by therapy area
Figure 107: Recent Genzyme partnering deals (2003-2008) where contract document available
Figure 108: Gilead – Dealmaking frequency 2000-2007
Figure 109: Gilead - recent deals (2005-2008) by deal type
Figure 110: Gilead - recent deals (2005 – 2008) by stage of development
Figure 111: Gilead – recent deals (2005 – 2008) by therapy area
Figure 112: Recent Gilead partnering deals (2003-2008) where contract document available
Figure 113: GlaxoSmithKline – Dealmaking frequency 2000-2007
Figure 114: GlaxoSmithKline - recent deals (2005-2008) by deal type
Figure 115: GlaxoSmithKline - recent deals (2005 – 2008) by stage of development
Figure 116: GlaxoSmithKline – recent deals (2005 – 2008) by therapy area
Figure 117: Recent GlaxoSmithKline partnering deals (2003-2008) where contract document available
Figure 118: Johnson & Johnson – Dealmaking frequency 2000-2007
Figure 119: Johnson & Johnson - recent deals (2005-2008) by deal type
Figure 120: Johnson & Johnson - recent deals (2005 – 2008) by stage of development
Figure 121: Johnson & Johnson – recent deals (2005 – 2008) by therapy area
Figure 122: Recent Johnson & Johnson partnering deals (2003-2008) where contract document available
Figure 123: King Pharmaceuticals – Dealmaking frequency 2000-2007
Figure 124: King - recent deals (2005-2008) by deal type
Figure 125: King - recent deals (2005 – 2008) by stage of development
Figure 126: King – recent deals (2005 – 2008) by therapy area
Figure 127: Recent King partnering deals (2003-2008) where contract document available
Figure 128: Lundbeck – Dealmaking frequency 2000-2007
Figure 129: Lundbeck - recent deals (2005-2008) by deal type
Figure 130: Lundbeck - recent deals (2005 – 2008) by stage of development
Figure 131: Lundbeck – recent deals (2005 – 2008) by therapy area
Figure 132: Recent Lundbeck partnering deals (2003-2008) where contract document available
Figure 133: Menarini – Dealmaking frequency 2000-2007
Figure 134: Menarini - recent deals (2005-2008) by deal type
Figure 135: Menarini - recent deals (2005 – 2008) by stage of development
Figure 136: Menarini – recent deals (2005 – 2008) by therapy area
Figure 137: Recent Menarini partnering deals (2003-2008) where contract document available
Figure 138: Merck & Co – Dealmaking frequency 2000-2007
Figure 139: Merck & Co - recent deals (2005-2008) by deal type
Figure 140: Merck & Co - recent deals (2005 – 2008) by stage of development
Figure 141: Merck & Co – recent deals (2005 – 2008) by therapy area
Figure 142: Recent Merck & Co partnering deals (2003-2008) where contract document available
Figure 143: Merck KGaA – Dealmaking frequency 2000-2007
Figure 144: Merck KGaA - recent deals (2005-2008) by deal type
Figure 145: Merck KGaA - recent deals (2005 – 2008) by stage of development
Figure 146: Merck KGaA – recent deals (2005 – 2008) by therapy area
Figure 147: Recent Merck KGaA partnering deals (2003-2008) where contract document available
Figure 148: Mitsubishi-Tanabe – Dealmaking frequency 2000-2007
Figure 149: Mitsubishi-Tanabe - recent deals (2005-2008) by deal type
Figure 150: Mitsubishi-Tanabe - recent deals (2005 – 2008) by stage of development
Figure 151: Mitsubishi-Tanabe – recent deals (2005 – 2008) by therapy area
Figure 152: Recent Mitsubishi-Tanabe partnering deals (2003-2008) where contract document available
Figure 208: Mundipharma – Dealmaking frequency 2000-2007
Figure 219: Mundipharma - recent deals (2005-2008) by deal type
Figure 220: Mundipharma - recent deals (2005 – 2008) by stage of development
Figure 221: Mundipharma – recent deals (2005 – 2008) by therapy area
Figure 222: Recent Mundipharma partnering deals (2003-2008) where contract document available
Figure 153: Novartis – Dealmaking frequency 2000-2007
Figure 154: Novartis - recent deals (2005-2008) by deal type
Figure 155: Novartis - recent deals (2005 – 2008) by stage of development
Figure 156: Novartis – recent deals (2005 – 2008) by therapy area
Figure 157: Recent Novartis partnering deals (2003-2008) where contract document available
Figure 158: Novo Nordisk – Dealmaking frequency 2000-2007
Figure 159: Novo Nordisk - recent deals (2005-2008) by deal type
Figure 160: Novo Nordisk - recent deals (2005 – 2008) by stage of development
Figure 161: Novo Nordisk – recent deals (2005 – 2008) by therapy area
Figure 162: Recent Novo Nordisk partnering deals (2003-2008) where contract document available
Figure 163: Nycomed – Dealmaking frequency 2000-2007
Figure 164: Nycomed - recent deals (2005-2008) by deal type
Figure 165: Nycomed - recent deals (2005 – 2008) by stage of development
Figure 166: Nycomed – recent deals (2005 – 2008) by therapy area
Figure 167: Recent Nycomed partnering deals (2003-2008) where contract document available
Figure 168: Otsuka – Dealmaking frequency 2000-2007
Figure 169: Otsuka - recent deals (2005-2008) by deal type
Figure 170: Otsuka - recent deals (2005 – 2008) by stage of development
Figure 171: Otsuka – recent deals (2005 – 2008) by therapy area
Figure 172: Recent Otsuka partnering deals (2003-2008) where contract document available
Figure 173: Pfizer – Dealmaking frequency 2000-2007
Figure 174: Pfizer - recent deals (2005-2008) by deal type
Figure 175: Pfizer - recent deals (2005 – 2008) by stage of development
Figure 176: Pfizer – recent deals (2005 – 2008) by therapy area
Figure 177: Recent Pfizer partnering deals (2003-2008) where contract document available
Figure 178: Procter & Gamble – Dealmaking frequency 2000-2007
Figure 179: Procter & Gamble - recent deals (2005-2008) by deal type
Figure 180: Procter & Gamble - recent deals (2005 – 2008) by stage of development
Figure 181: Procter & Gamble – recent deals (2005 – 2008) by therapy area
Figure 182: Recent Procter & Gamble partnering deals (2003-2008) where contract document available
Figure 208: Ratiopharm – Dealmaking frequency 2000-2007
Figure 219: Ratiopharm - recent deals (2005-2008) by deal type
Figure 220: Ratiopharm - recent deals (2005 – 2008) by stage of development
Figure 221: Ratiopharm – recent deals (2005 – 2008) by therapy area
Figure 222: Recent Ratiopharm partnering deals (2003-2008) where contract document available
Figure 183: Roche – Dealmaking frequency 2000-2007
Figure 184: Roche - recent deals (2005-2008) by deal type
Figure 185: Roche - recent deals (2005 – 2008) by stage of development
Figure 186: Roche – recent deals (2005 – 2008) by therapy area
Figure 187: Recent Roche partnering deals (2003-2008) where contract document available
Figure 188: Sanofi-Aventis – Dealmaking frequency 2000-2007
Figure 189: Sanofi-Aventis - recent deals (2005-2008) by deal type
Figure 190: Sanofi-Aventis - recent deals (2005 – 2008) by stage of development
Figure 191: Sanofi-Aventis – recent deals (2005 – 2008) by therapy area
Figure 192: Recent Sanofi-Aventis partnering deals (2003-2008) where contract document available
Figure 193: Schering Plough – Dealmaking frequency 2000-2007
Figure 194: Schering Plough - recent deals (2005-2008) by deal type
Figure 195: Schering Plough - recent deals (2005 – 2008) by stage of development
Figure 196: Schering Plough – recent deals (2005 – 2008) by therapy area
Figure 197: Recent Schering Plough partnering deals (2003-2008) where contract document available
Figure 208: Servier – Dealmaking frequency 2000-2007
Figure 219: Servier - recent deals (2005-2008) by deal type
Figure 220: Servier - recent deals (2005 – 2008) by stage of development
Figure 221: Servier – recent deals (2005 – 2008) by therapy area
Figure 222: Recent Servier partnering deals (2003-2008) where contract document available
Figure 198: Shire – Dealmaking frequency 2000-2007
Figure 199: Shire - recent deals (2005-2008) by deal type
Figure 200: Shire - recent deals (2005 – 2008) by stage of development
Figure 201: Shire – recent deals (2005 – 2008) by therapy area
Figure 202: Recent Shire partnering deals (2003-2008) where contract document available
Figure 203: Solvay – Dealmaking frequency 2000-2007
Figure 204: Solvay - recent deals (2005-2008) by deal type
Figure 205: Solvay - recent deals (2005 – 2008) by stage of development
Figure 206: Solvay – recent deals (2005 – 2008) by therapy area
Figure 207: Recent Solvay partnering deals (2003-2008) where contract document available
Figure 208: Stada – Dealmaking frequency 2000-2007
Figure 219: Stada - recent deals (2005-2008) by deal type
Figure 220: Stada - recent deals (2005 – 2008) by stage of development
Figure 221: Stada – recent deals (2005 – 2008) by therapy area
Figure 222: Recent Stada partnering deals (2003-2008) where contract document available
Figure 208: Takeda – Dealmaking frequency 2000-2007
Figure 209: Takeda - recent deals (2005-2008) by deal type
Figure 210: Takeda - recent deals (2005 – 2008) by stage of development
Figure 211: Takeda – recent deals (2005 – 2008) by therapy area
Figure 212: Recent Takeda partnering deals (2003-2008) where contract document available
Figure 208: Teva – Dealmaking frequency 2000-2007
Figure 219: Teva - recent deals (2005-2008) by deal type
Figure 220: Teva - recent deals (2005 – 2008) by stage of development
Figure 221: Teva – recent deals (2005 – 2008) by therapy area
Figure 222: Recent Teva partnering deals (2003-2008) where contract document available
Figure 213: UCB Group – Dealmaking frequency 2000-2007
Figure 214: UCB Group - recent deals (2005-2008) by deal type
Figure 215: UCB Group - recent deals (2005 – 2008) by stage of development
Figure 216: UCB Group – recent deals (2005 – 2008) by therapy area
Figure 217: Recent UCB Group partnering deals (2003-2008) where contract document available
Figure 218: Watson – Dealmaking frequency 2000-2007
Figure 219: Watson - recent deals (2005-2008) by deal type
Figure 220: Watson - recent deals (2005 – 2008) by stage of development
Figure 221: Watson – recent deals (2005 – 2008) by therapy area
Figure 222: Recent Watson partnering deals (2003-2008) where contract document available
Figure 223: Wyeth – Dealmaking frequency 2000-2007
Figure 224: Wyeth - recent deals (2005-2008) by deal type
Figure 225: Wyeth - recent deals (2005 – 2008) by stage of development
Figure 226: Wyeth – recent deals (2005 – 2008) by therapy area
Figure 227: Recent Wyeth partnering deals (2003-2008) where contract document available
Figure 228: Online partnering resources
Figure 229: Development and license agreement between Boehringer Ingelheim and Inspire Pharmaceuticals, February 2006 |
|
Summary: |
This report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies. One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 200 charts allow quick understanding of each bigpharma companies dealmaking trends over the last four years.
One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship. Understanding the flexibility of a prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains over 1,000 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners. In addition, contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.
The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities:
Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues and dealmaking activity since 2005.
Chapter 3 analyzes the most active dealmakers since 2005 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-8 according to reported deal size.
Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.
Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.
The main body of the report is provided in chapter 7 and 8.
Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last two years.
Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. Each profile also includes in-depth contact information for individuals within the business development function.
In summary, the report provides the reader with the tools necessary to make successful contact with the right bigpharma partners effectively and efficiently:
- Detailed company profile for the top 50 bigpharma
- In-depth marketed and pipeline product activity of each company
- Partnering interests and therapy focus revealed
- Partnering activity since 2000 – number of deals per year
- Partnering activity for 2005-2008
- Activity by deal type
- Activity by phase of development
- Activity by therapeutic area
- List of recent partner companies
- Direct contact information for over 1,000 bigpharma dealmakers – name, title, email, telephone details, where available
- General company and partnering contact information
- List of contract documents available to allow analysis of bigpharma deal terms – each linked to an online copy of the actual contract as filed at the SEC. |
|
Companies Mentioned |
Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Barr Pharmaceuticals
Baxter International
Bayer
Biogen Idec
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Chugai
CSL
Daiichi Sankyo
Eisai
Eli Lilly
Forest Laboratories
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
King
Lundbeck
Menarini
Merck & Co
Merck Serono KGaA
Mitsubishi-Tanabe
Mundipharma
Novartis AG
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Procter & Gamble
Ratiopharm
Roche
Sanofi-Aventis
Schering Plough
Servier
Shire
Solvay
Stada
Takeda
Teva
UCB
Watson
Wyeth |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/614523
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 02/12/2008 07:28:00 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Partnering with Bigpharma: The Definitive Guide to Partnering Interests, Contacts & Agreements
|
|
Web Address: |
http://www.researchandmarkets.com/reports/614523
|
|
Office Code: |
|
OCIFGMNTVWS
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Single User
|
|
€2,378.00
|
|
CD ROM
|
|
€2,378.00 + EUR€ 50.00 Shipping/Handling *
|
|
Electronic (PDF)
- Site License
|
|
€7,141.00
|
|
Hard Copy
|
|
€2,695.00 + EUR€ 50.00 Shipping/Handling *
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
Page 2 of 2
Printed 02/12/2008 07:28:00
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder Name: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
|
|
|
|
